Danaher Q3 2026 Earnings: Core Growth Excluding Respiratory Testing Reaches 5.5%

Danaher (NYSE: DHR) reported Q3 2026 revenue of $6.554 billion, up 8.5% year over year, while diluted EPS from continuing operations increased to $1.71 from $1.27. Core revenue growth excluding respiratory testing accelerated to 5.5%, and free cash flow rose 19% even as respiratory testing remained a drag on underlying growth.

Core Earnings Data

For the quarter ended September 25, 2026, total core revenue grew 3.0%, below reported growth because acquisitions and divestitures contributed materially to the top line. Excluding respiratory testing, core growth reached 5.5%, indicating better underlying performance across the rest of the portfolio.

Operating profit increased 7.9%, but operating margin was approximately flat. Net earnings grew much faster because Danaher recorded a tax benefit, including $263 million of net discrete benefits primarily related to the release of reserves following tax audit settlements.

Margins and margin changes are approximate calculations based on the reported financial statements. Adjusted EPS and free cash flow are non-GAAP measures.

Business and Segment Performance

Reported growth and underlying growth diverged across Danaher’s segments. Acquisition and divestiture effects accounted for approximately 6.5 percentage points of companywide reported growth and 16.5 points in Diagnostics.

Diagnostics posted the highest reported growth, but respiratory testing reduced its core growth by 6.5 percentage points. Biotechnology and Life Sciences delivered stronger core growth than their reported figures indicated.

Respiratory testing revenue was approximately $350 million, down from approximately $500 million a year earlier. These figures are rounded to the nearest $50 million. Beginning in Q3 2026, Danaher also excluded tariff refunds returned or expected to be returned to customers from its core sales calculations; the reconciliation included a 1-percentage-point companywide adjustment and a 4-point Biotechnology adjustment for these refunds.

Profitability and Cash Flow

Gross margin improved modestly to approximately 58.55%, but the gain did not translate into operating margin expansion. Selling, general and administrative expenses rose to $2.159 billion from $1.991 billion, while research and development spending increased to $433 million from $378 million. As a result, operating margin remained near 19%.

Cash generation strengthened in absolute terms. Operating cash flow increased 13.5%, while lower capital expenditures of $255 million, versus $292 million a year earlier, helped free cash flow grow 19%.

Cash conversion ratios nevertheless declined because net earnings increased faster than cash flow. Operating cash flow represented 1.56 times continuing-operations net earnings, down from 1.83 times, while free cash flow conversion decreased to 1.35 times from 1.51 times.

Tax Benefits Lifted GAAP EPS Faster Than Operating Profit

The gap between GAAP and adjusted earnings growth was a central feature of the quarter. Operating profit rose 7.9% and pretax earnings increased approximately 5.2%, but diluted EPS from continuing operations grew 34.6%.

Danaher recorded a $75 million income tax benefit, compared with $168 million of tax expense in Q3 2025. This included $263 million of net discrete tax benefits, primarily from releasing reserves for uncertain tax positions following audit settlements. The period-specific tax benefit therefore amplified GAAP earnings growth, while the 11.5% increase in adjusted EPS more closely tracked the underlying improvement after Danaher’s specified adjustments.

Earnings Guidance

Danaher raised and narrowed its full-year adjusted EPS guidance. The lower end increased by $0.12 and the upper end by $0.02, moving the range to $8.57-$8.62 from $8.45-$8.60.

For Q4, management expects core revenue excluding respiratory testing to grow 4% to 5%. An anticipated respiratory testing headwind of approximately 150 basis points is expected to reduce total core growth to about 3%.

The operating margin, core revenue, and adjusted EPS forecasts are non-GAAP measures.

Management’s View

CEO Julie Sawyer Montgomery attributed the double-digit adjusted EPS growth to accelerating core revenue excluding respiratory testing and execution through the Danaher Business System. She also pointed to improving end-market trends and identified sustainable growth and market-share gains in Life Sciences and Diagnostics as the company’s strategic priorities.

Risks Investors Need to Watch

• Respiratory testing remains volatile. Q3 respiratory revenue declined to approximately $350 million from $500 million, and management expects it to create another 150-basis-point core growth headwind in Q4.
• Reported growth relied materially on acquisitions. Acquisition and divestiture effects represented about 6.5 percentage points of companywide growth and 16.5 points in Diagnostics. Integration execution is therefore important to converting acquired revenue into sustainable core growth.
• Financing costs have increased. Danaher identified debt incurred to finance the Masimo acquisition as a risk, while quarterly interest expense rose to $135 million from $67 million.
• Tariffs and customer refunds can affect reported revenue. The new core-sales definition excludes specified tariff refunds to customers, and the Q3 reconciliation showed a particularly large adjustment in Biotechnology.
• GAAP earnings included a significant discrete tax benefit. The $263 million benefit boosted reported EPS growth relative to operating and adjusted earnings, making it important to separate period-specific tax effects from the underlying profit trend.

Summary

Danaher’s Q3 2026 results showed improving underlying demand, with core growth excluding respiratory testing reaching 5.5% and free cash flow increasing 19%. Acquisitions contributed substantially to reported revenue growth, while a discrete tax benefit lifted GAAP EPS well above the pace of operating profit growth. The raised full-year adjusted EPS range is constructive, but Q4 respiratory testing pressure, acquisition integration, higher interest expense, and tariff-related effects remain the main items to monitor.